Participant flow

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma · Source last updated 2016-02-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pazopanib 800 mg (tablets) administered orally once a day

   id

   FG000

   title

   Pazopanib 800 mg

2. description

   Matching Placebo administered orally once a day

   id

   FG001

   title

   Placebo

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         5

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         17

      2. group Id

         FG001

         num Subjects

         3

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         194

      2. group Id

         FG001

         num Subjects

         100

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         290

      2. group Id

         FG001

         num Subjects

         145

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         68

      2. group Id

         FG001

         num Subjects

         37

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         222

      2. group Id

         FG001

         num Subjects

         108

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice